DEFA 14A 2023

Washington, D.C. 20549
(Rule 14a-101)

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant
Filed by a Party other than the Registrant
Check the appropriate box:
Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to §240.14a-12
Pliant Therapeutics, Inc.
(Exact name of registrant as specified in its charter) 
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
Fee paid previously with preliminary materials.

Your Vote Counts! PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO, CA 94080 PLIANT THERAPEUTICS, INC. 2023 Annual Meeting Vote by June 6, 2023 11:59 PM ET You invested in PLIANT THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 7, 2023. *Please check the meeting materials for instructions on attending the virtual annual meeting. Smartphone users Point your camera here and vote without entering a control number V1.1 For complete information and to vote, visit Control # V12565-P90971 Get informed before you vote View the Proxy Statement and our 2022 Annual Report to Stockholders on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 24, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit, (2) call 1-800-579-1639 or (3) send an email to If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually During the Annual Meeting* June 7, 2023 8:30 a.m. Pacific Time Virtually at:

THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at Voting Items Board Recommends V12566-P90971 Prefer to receive an email instead? While voting on, be sure to click “Delivery Settings”. 1. To elect three class III directors named in the proxy statement to our Board of Directors: Nominees: 1c. Suzanne Bruhn, Ph.D. 1a. Bernard Coulie, M.D., Ph.D. 2. To approve, by non-binding advisory vote, the resolution approving named executive officer compensation. 1b. Gayle Crowell NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the meeting. For For For For For 3. To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.